ALK and breast cancer: Pathologists also use immunostains to provide information on the prognosis (for example, “triple-negative” breast cancer usually follows an aggressive course, whereas ALK-positivity portends a favorable prognosis in anaplastic large cell lymphoma [161]), or guide clinical treatment decisions.